SDHB and neoplastic syndrome: If an SDHB germline mutation is identified in a patient with HNPGL, the clinician should be aware of the variable manifestations of the SDHB‐linked tumour syndrome and, irrespective of the chosen management strategy, periodic surveillance should be performed including screening for catecholamine excess, concurrent PGL or phaeochromocytoma, metastatic PGL and SDHB‐associated non‐paraganglionic tumours.